Jasmine Zain, MD, on the most exciting studies in lymphoma presented at ASH 2018

Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, shares details of the most exciting studies in lymphoma presented at the 2018 ASH Annual Meeting and Exposition

Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, ...

Yana Pikman, MD, regarding research outcomes from the LEAP Consortium

Dr. Pikman, Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Children’s Hospital, explains how the results of the LEAP Consortium’s clinical study may help identify mutations that can improve outcomes in pediatric acute leukemia

Dr. Pikman, Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Children’s Hospital, explains how the results of the LEAP Consortium’s ...

Jasmine Zain, MD, discusses novel treatment research regarding transplants at City of Hope

Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses novel treatment research regarding transplants

Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses ...

Jasmine Zain, MD, considers the impact of the new induction regimen in PTCL

Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, provides opinion on whether the standard of care in the treatment of peripheral T-cell lymphoma (PTCL) is changing as a result of the new induction regimen

Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, ...

Yana Pikman, MD, on the efforts of the LEAP Consortium in pediatric acute leukemia

Dr. Pikman, Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Children’s Hospital, explains the LEAP Consortium and how the group is developing actionable genomic targets in pediatric acute leukemia

Dr. Pikman, Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Children’s Hospital, explains the LEAP Consortium and how the group ...

Jasmine Zain, MD, defines successful induction regimens when treating PTCL

Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses what contributes to a successful induction regimen when treating peripheral T-cell lymphoma (PTCL) patients

Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses ...

Jasmine Zain, MD, elaborates on the investigation of novel induction regimens in PTCL

Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, tells us about the investigation of novel induction regimens prior to ASCT for the treatment of peripheral T-cell lymphoma (PTCL)

Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, tells ...

Jasmine Zain, MD, regarding the standard of care in treatment of PTCL

Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, explains how has the standard of care in the treatment of peripheral T-cell lymphoma (PTCL) has changed in the last several years

Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, explains ...

Carol Moreno, MD, PhD, discusses MRD as a legitimate surrogate marker in CLL

Dr. Moreno, Hematologist, University of Barcelona, considers whether minimal residual disease (MRD) is a legitimate surrogate marker for response and risk of recurrence when treating chronic lymphocytic leukemia (CLL)

Dr. Moreno, Hematologist, University of Barcelona, considers whether minimal residual disease (MRD) is a legitimate surrogate marker for response and ...

Carol Moreno, MD, PhD, describes recent advancements in the treatment of CLL

Dr. Moreno, Hematologist, University of Barcelona, elaborates on recent advancements in the treatment of chronic lymphocytic leukemia (CLL)

Dr. Moreno, Hematologist, University of Barcelona, elaborates on recent advancements in the treatment of chronic lymphocytic leukemia (CLL)